# Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Article · Sean Wharton, Salvatore Calanna, Melanie Jane Davies, Dror Dicker, Bryan Goldman, Ildiko Lingvay, Ofri Mosenzon, Domenica Rubino, Mette Thomsen, Thomas A. Wadden, Sue D. Pedersen

- Archive id: doi:10.1111/dom.14551
- Published: 2021-09-13
- Venue: Diabetes Obesity and Metabolism
- DOI: https://doi.org/10.1111/dom.14551
- PMID: 34514682
- Citations: 199
- Source URL: https://doi.org/10.1111/dom.14551
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.